{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:21:13Z","timestamp":1783110073429,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.xphs.2018.11.023","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T19:12:07Z","timestamp":1542913927000},"page":"1590-1597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach"],"prefix":"10.1016","volume":"108","author":[{"given":"Puneet","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Pechenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"RiosDoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall J.","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenlan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok","family":"Yo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anand","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2018.11.023_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm001064n","article-title":"Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity","volume":"44","author":"Gregson","year":"2001","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.xphs.2018.11.023_bib2","series-title":"11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one Derivatives as Key Intermediates for the Preparation of C2 Substituted Pyrrolobenzodiazepines","author":"Howard","year":"2005"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.023_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"9","key":"10.1016\/j.xphs.2018.11.023_bib4","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1128\/AEM.02326-08","article-title":"Biosynthesis of sibiromycin, a potent antitumor antibiotic","volume":"75","author":"Li","year":"2009","journal-title":"Appl Environ Microbiol"},{"issue":"302","key":"10.1016\/j.xphs.2018.11.023_bib5","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A\u00a0DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in\u00a0vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"issue":"17","key":"10.1016\/j.xphs.2018.11.023_bib6","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1158\/0008-5472.CAN-10-0790","article-title":"SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity","volume":"70","author":"Hartley","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.xphs.2018.11.023_bib7","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/cr100120f","article-title":"Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)","volume":"111","author":"Antonow","year":"2011","journal-title":"Chem Rev"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152009787047743","article-title":"Pyrrolo[2,1-c][1,4]benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs","volume":"9","author":"Cipolla","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.023_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/med.20212","article-title":"Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines","volume":"32","author":"Gerratana","year":"2012","journal-title":"Med Res Rev"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.11.023_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2007.03.012","article-title":"Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody","volume":"120","author":"Kocbek","year":"2007","journal-title":"J\u00a0Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.xphs.2018.11.023_bib12","series-title":"Degradable Polymers","first-page":"71","article-title":"Biodegradation of aliphatic polyesters","author":"Scott","year":"2002"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02980037","article-title":"Control of encapsulation efficiency and initial burst in polymeric microparticle systems","volume":"27","author":"Yeo","year":"2004","journal-title":"Arch Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2018.11.023_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jbm.820190315","article-title":"Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules","volume":"19","author":"Visscher","year":"1985","journal-title":"J\u00a0Biomed Mater Res"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03639048109055684","article-title":"Development of biodegradable and injectable lattices for controlled release of potent drugs","volume":"7","author":"Gurny","year":"1981","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.023_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jps.2600690222","article-title":"Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles","volume":"69","author":"Couvreur","year":"1980","journal-title":"J\u00a0Pharm Sci"},{"issue":"128","key":"10.1016\/j.xphs.2018.11.023_bib17","doi-asserted-by":"crossref","first-page":"128ra139","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2018.11.023_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"325","key":"10.1016\/j.xphs.2018.11.023_bib19","doi-asserted-by":"crossref","first-page":"325ra317","DOI":"10.1126\/scitranslmed.aad2355","article-title":"Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in\u00a0vivo","volume":"8","author":"Ashton","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.023_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejpb.2008.09.003","article-title":"Lipid nanoparticles for parenteral delivery of actives","volume":"71","author":"Joshi","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2018.11.023_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2015.03.019","article-title":"Comparative biodistribution in mice of cyanine dyes loaded in lipid nanoparticles","volume":"93","author":"Merian","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2018.11.023_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.nano.2012.08.005","article-title":"Influence of size, surface coating and fine chemical composition on the in\u00a0vitro reactivity and in\u00a0vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models","volume":"9","author":"Hirsjarvi","year":"2013","journal-title":"Nanomedicine"},{"issue":"3-4","key":"10.1016\/j.xphs.2018.11.023_bib23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejps.2009.04.008","article-title":"Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin","volume":"37","author":"Subedi","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2018.11.023_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jps.22342","article-title":"Controlling ligand surface density optimizes nanoparticle binding to ICAM-1","volume":"100","author":"Fakhari","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2018.11.023_bib25","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jps.20094","article-title":"Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA\/PLA nanoparticles","volume":"93","author":"Panyam","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.023_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/02652049709015330","article-title":"Effect of processing parameters on the properties of peptide-containing PLGA microspheres","volume":"14","author":"Jeyanthi","year":"1997","journal-title":"J\u00a0Microencapsul"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.11.023_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0378-5173(88)90073-7","article-title":"Solvent selection in the preparation of poly(Dl-lactide) microspheres prepared by the solvent evaporation method","volume":"43","author":"Bodmeier","year":"1988","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.xphs.2018.11.023_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.xphs.2018.11.023_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.xphs.2018.11.023_bib31","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-04-2445","article-title":"Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes","volume":"11","author":"Drummond","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.023_bib32","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1038\/s41467-018-06271-5","article-title":"Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2018.11.023_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2018.01.009","article-title":"Nanotherapeutics in oral and parenteral drug delivery: key learnings and future outlooks as we think small","volume":"272","author":"Tyagi","year":"2018","journal-title":"J\u00a0Control Release"},{"issue":"11","key":"10.1016\/j.xphs.2018.11.023_bib34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med Chem Lett"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918307275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918307275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T08:42:00Z","timestamp":1565253720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918307275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0022354918307275"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.11.023","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}